Tratamiento médico de la vitreorretinopatía
proliferative vitreoretinopathy. 40 consecutive patients were assigned to a control group and the other 40 received oral colchicine (1.5 mg/day). Medication started the first day after surgery and continued for four weeks. The follow-up period was three months. Data obtained in both groups were compared.
Texto en PDF